Hope you all are doing good and taking proper precautions.
We recently shared our new stock recommendation with our Premium Members and would like to share with you details about the same.
As discussed in our Risk categorization update, we have been focusing on leading well-managed companies which will probably emerge stronger from this pandemic and capture higher market share in the years to come. Have also benefited from this strategy with stocks like Aarti Drugs, Suven Pharma, Chaman Lal, Manappuram, Asahi Songwon, FIEM Industries, etc. appreciating by 100-400% in the last few months.
Also, if such companies come debt free and with low valuations, one can only blame himself for not buying such stocks during periods of distress.
If you believe in investing in Growth Stocks at Reasonable Valuations, you may find our latest stock report and the thesis behind the same interesting. The stock report was shared yesterday only with Premium Members and included in the Model Sheet.
Disclosure: I have personal investment in the stock and bought it on 25th Sep’20
Our Model Sheets have delivered 23% + return in around 2 years against -3% to -24.5% by NIFTY and other benchmark indices. You can read about it HERE
You can access latest Investment Reports, Special situation opportunities and Model sheets in Premium Memberships at the following LINK
Latest Stock Recommendation
The company we are talking about has the following attributes:
- Market cap > 1,000 crore
- FY 10-FY 19 – ~15% CAGR in sales, 18.5% CAGR in Profits
- Dividend – Consistently paying since 10-11 years
- Debt – Debt free at the end of Jun’20 with some surplus cash
- Avg. Return on Equity (ROE) – 16% + for the last 8 years
- Valuations – Available at around 11.68 times 4 years avg. PAT
- CAPEX – CAPEX of more than 100 crore planned for the next 2 years and will be funded entirely out of internal accruals
- Promoter stake – Higher than 50% with further addition through open market purchases in the month of Mar’20
- Growth Plans – CAPEX for backward integration, New Formulations unit at SEZ for growing exports by more than 300%, launch of new products and replacement of generic products with high margin new launches
Between FY 20-FY 23 we expect the company to record 11-12% CAGR in sales and double its PAT to around Rs 150 crore. Higher growth in PAT is expected on the back of 200-300 bps expansion in Gross and EBITDA margins and reduction in finance cost by around 15-20 crore.
Over the last 10 years, the stock has largely traded in the range of 10-30 times earnings. Assuming 15 times FY 23 earnings, the stock can more than double over the next 3 years.
These days there’re a few decent sized debt free companies with strong operating track record and good outlook available at 10-12 times earnings and yet investors are not willing to touch them even with a barge pole.
A few years down the line many might end up substantially higher and would appear no-brainer then.
Wish you good health and wealth.
Details of Associates: Not Applicable
Analyst Certification: The Analyst certify (ies) that the views expressed herein accurately reflect his (their) personal view(s) about the subject security (ies) and issuer(s) and that no part of his (their) compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report
Disclaimer: www.katalystwealth.com (here in referred to as Katalyst Wealth) is the domain owned by Ekansh Mittal. Mr. Ekansh Mittal is the sole proprietor of Mittal Consulting and offers independent equity research services to Investors on subscription basis. SEBI (Research Analyst) Regulations 2014, Registration No. INH100001690
The views expressed are based solely on information available publicly and believed to be true. Investors are advised to independently evaluate the market conditions/risks involved before making any investment decision
A graph of daily closing prices of securities is available at www.bseindia.com (Choose a company from the list on the browser and select the “three years” period in the price chart.
This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Ekansh Mittal/Mittal Consulting/Katalyst Wealth is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form. This document is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Ekansh Mittal or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Neither Ekansh Mittal, nor its employees, agents nor representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. Ekansh Mittal/Mittal Consulting or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement.
The recipients of this report should rely on their own investigations. Ekansh Mittal/Mittal Consulting and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Mittal Consulting has incorporated adequate disclosures in this document. This should, however, not be treated as endorsement of the views expressed in the report.
We submit that no material disciplinary action has been taken on Ekansh Mittal by any regulatory authority impacting Equity Research Analysis.
Disclosure (SEBI RA Regulations)
Whether the research analyst or research entity or his associate or his relative has any financial interest in the subject company/companies and the nature of such financial interest – Investment in Suven Pharma, Manappuram Finance and FIEM Industries. Also Aarti Drugs in wife’s and father’s account.
Whether the research analyst or research entity or his associates or his relatives have actual/beneficial ownership of 1% or more securities of the subject company (at the end of the month immediately preceding the date of publication of the research report or date of the public appearance) – No
Whether the research analyst or research entity or his associate or his relative has any other material conflict of interest at the time of publication of the research report or at the time of public appearance – No
Whether it or its associates have received any compensation from the subject company in the past twelve months – No
Whether it or its associates have managed or co-managed public offering of securities for the subject company in the past 12 months – No
Whether it or its associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No
Whether it or its associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No
Whether the subject company is or was a client during twelve months preceding the date of distribution of the research report and the types of services provided – No
Whether the research analyst has served as an officer, director or employee of the subject company – No
Whether the research analyst or research entity has been engaged in market making activity for the subject company – No